Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?

Key Takeaways NVO's Ozempic and Wegovy generated DKK 50.1B in Q1 sales, making up 66% of total revenues. Label expansions and stronger access programs have fueled higher demand for semaglutide drugs. NVO secured a U.S. ban on mass compounding and is expanding Wegovy access via CVS and NovoCare.Novo Nordisk (NVO) generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same compound, semaglut ...